Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CLL1 CAR-T in Relapsed/Refractory AML
NCT04923919Phase 1Unknown
- Start
- Sep 2021
- Primary completion
- Dec 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of anti-CLL-1 CAR-T in acute myeloid leukemia (AML). Primary endpoint: Incidence of Adverse Events at 12 months. Status: unknown.
02
Drugs
anti-CLL-1 CAR-T
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04923919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04923919.